Oncopeptides has announced that the company has decided to withdraw Pepaxto (INN melphalan flufenamide) from the market in the US, following the phase 3 OCEAN study, which showed an overall
Nordic Life Science
Pharma news from the Nordic life science industry
Latest news
Novo Nordisk has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna) for a total equity value of approximately USD 3.3 billion. The acquisition of Dicerna’s ribonucleic acid interference
The new name and identity signifies a new phase of growth for the company and the agreement with US-based Regeneron is worth up to 900 million USD. The multi-target license
Devyser Diagnostics has announced its intention to launch an initial public offering of its shares and to list its shares on Nasdaq First North Premier Growth Market. The offering is
Affibody has announced a partnership agreement with ACELYRIN to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple autoimmune diseases. Under the terms of the agreement, Affibody
Valo Therapeutics has successfully raised 11 million EUR in an oversubscribed Pre-IPO funding round. The Pre-IPO fund included participation from existing investors, Freeman Road, and new investors, including ASX-listed MMJ
This financing round was raised from US, Irish and Swedish investors. Several family offices, among them Hans and Barbara Bergström, and the Mattsson family, founder of spice giant Santa Maria
The global pharmaceutical company Organon is acquiring its portfolio company Forendo Pharma. Forendo Pharma’s shareholders will receive an initial payment of USD 75 million and are entitled to additional future
BerGenBio has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for bemcentinib in combination with an anti-PD-(L)1 agent as treatment for patients with STK11
Business angels and venture capital companies Stoaf III SciTech, Phase2Phase Biopharma and Partnerinvest Norr are backing Vakona with investments totaling SEK 15 million. “We are absolutely delighted and proud to have
SAGA Diagnostics has entered into an assay development agreement with AstraZeneca. SAGA Diagnostics will in the course of this agreement develop SAGAsafe dPCR assays towards undisclosed methylated targets for analyses
Clinical trials
The company’s universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab, has recently demonstrated a 60% objective response rate in metastatic malignant melanoma. Nordic Life Science asked the
BerGenBio will deliver an e-poster presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, including pre-clinical and clinical data suggesting that bemcentinib restored response to anti-PD-1 treatments
Lundbeck has expanded its clinical-stage pipeline and initiates the AMULET study, which is designed to confirm the potential of Lu AF82422 as a treatment to slow the rate of disease
Ultimovacs has announced data showing that the company’s universal cancer vaccine UV1 in combination with ipilimumab induces dynamic, multi-functional T cell responses in patients with melanoma, with the potential for
Medivir has announced that IGM Biosciences has initiated its clinical study in solid cancers with birinapant (a k a IGM-9427) in combination with IGM’s DR5 agonist antibody IGM-8444. The combination
Lundbeck has announced positive results from the DELIVER study assessing the efficacy and safety of Vyepti (eptinezumab) 100mg and 300mg IV infusion in patients with chronic or episodic migraine who
BioInvent International has announced additional positive interim data from its novel anti-FcγRIIB antibody BI-1206. The data update comes from the company’s Phase 1/2a clinical trial of BI-1206 in combination with
Ultimovacs’s universal cancer vaccine, UV1, will be investigated in a new Phase II clinical trial in combination with pembrolizumab in non-small cell lung cancer (NSCLC). The first patient is expected
Positive results from the TOPAZ-1 Phase III trial showed Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone
Sustainability
Pharmaceuticals in the environment is a growing problem of global concern. Drugs taken by humans and animals find their way into rivers, lakes and even drinking water and can have
CDMO Recipharm has announced that its 2020 International Environmental Award will be presented to Amy Pruden, Professor of Civil and Environmental Engineering at Virginia Tech in Blacksburg, Virginia, US. Amy
The professorship at the University of Helsinki, which is being established with the support of a fund, is aimed at strengthening sustainable development expertise in pharmacy across the globe. The
IVL Swedish Environmental Research Institute and Simrishamn Municipality have tested a completley new treatment system that has now been added to the Stengården sewage plant in Simrishamn, Sweden. “Removing pharmaceutical
Nordic efforts to prevent pharmaceuticals affecting the environment include Danish management of hospital wastewater and a Swedish large-scale sewage plant for removal of pharmaceutical residues. Wastewater from hospitals can contain